Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells  by Selak, Mary A. et al.
a 1757 (2006) 567–572
http://www.elsevier.com/locate/bbaBiochimica et Biophysica ActRedox stress is not essential for the pseudo-hypoxic phenotype of succinate
dehydrogenase deficient cells
Mary A. Selak, Raứl V. Durán, Eyal Gottlieb⁎
Apoptosis and Tumour Physiology Laboratory, Cancer Research UK, Beatson Institute for Cancer Research, Glasgow G61 1BD, Scotland, UK
Received 13 December 2005; received in revised form 29 April 2006; accepted 10 May 2006
Available online 17 May 2006Abstract
HIFα prolyl hydroxylases (PHDs) are a family of enzymes that regulate protein levels of the α subunit of the hypoxia inducible transcription
factor (HIF) under different oxygen levels. PHDs catalyse the conversion of a prolyl residue, molecular oxygen and α-ketoglutarate to hydroxy-
prolyl, carbon dioxide and succinate in a reaction dependent on ferrous iron and ascorbate as cofactors. Recently it was shown that pseudo-
hypoxia, HIF induction under normoxic conditions, is an important feature of tumours generated as a consequence of inactivation of the
mitochondrial tumour suppressor ‘succinate dehydrogenase’ (SDH). Two models have been proposed to describe the link between SDH inhibition
and HIF activation. Both models suggest that a mitochondrial-generated signal leads to the inhibition of PHDs in the cytosol, however, the models
differ in the nature of the proposed messenger. The first model postulates that mitochondrial-generated hydrogen peroxide mediates signal
transduction while the second model implicates succinate as the molecular messenger which leaves the mitochondrion and inhibits PHDs in the
cytosol. Here we show that pseudo-hypoxia can be observed in SDH-suppressed cells in the absence of oxidative stress and in the presence of
effective antioxidant treatment.
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Succinate dehydrogenase (SDH) couples the oxidative
dehydrogenation of succinate to the reduction of ubiquinone
and thereby functions as a member of both the Krebs
(tricarboxylic acid; TCA) cycle and the electron transport
chain (ETC-complex II). SDH is comprised of four protein
subunits (SDHA-D) which utilize FAD, iron–sulphur centres,
haemb and ubiquinone as prosthetic groups (for more details,
see [1,2]). Interestingly, despite its crucial role in energy
metabolism, SDH inactivation has been shown to be
associated with the formation of several types of tumours,
primarily paraganglioma (including functional paraganglioma
or phaeochromocytoma) [3–5]. Initially, mutations in SDHB,
SDHC and SDHD were discovered in families with
hereditary paraganglioma syndrome (HPGL) but very soon⁎ Corresponding author.
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doi:10.1016/j.bbabio.2006.05.015thereafter it was shown that somatic mutations in these genes
(particularly SDHB and SDHD) also play a role in a
significant number of sporadic paragangliomas [6,7]. Re-
cently, a link between SDHB mutations and renal cell and
thyroid carcinomas has also been described [8]. Despite
extensive genetic evidence demonstrating the importance of
SDH inactivation in the formation of these tumours, very
little biochemical evidence has been provided which clarifies
the relationship between SDH inactivation and tumorigene-
sis. One important biochemical link was elucidated from
studies in the nematode C. elegans [9,10]. In this work, it
was shown that a mutation in the C. elegans SDHC gene
(Mev-1) leads to the accumulation of reactive oxygen species
(ROS). More recently, it has been shown that the relevant
murine SDHC mutant can also induce ROS production when
transfected into mouse fibroblasts, leading to accelerated
mutagenesis of nuclear DNA in these cells [11].
One hallmark of tumours generated due to SDH
inactivation is pseudo-hypoxia, a condition in which cells
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is principally characterised by the activation of the hypoxia
inducible transcription factor (HIF) and its target genes,
leading to accelerated glycolysis and blood vessel growth
[12–16]. The best-characterised route of regulating HIF
activity is by a group of three HIFα prolyl hydroxylases
(PHDs) which hydroxylate and destabilize the HIFα subunit
of the HIF α/β heterodimer [17]. PHDs are members of a
larger family of α-ketoglutarate-dependent dioxygenases
which utilize molecular oxygen to hydroxylate their protein
targets on specific prolyl residues and are therefore important
oxygen sensors in cells [18]. Once hydroxylated, HIFα binds
to pVHL which is part of an E3 ubiquitin ligase complex that
ubiquitylates and targets HIFα for proteasomal-mediated
degradation. Importantly, PHDs require ferrous iron and
ascorbate for activity and hydrogen peroxide was shown to
oxidise these cofactors, thereby inhibiting PHD and leading to
HIFα stabilization [19]. Furthermore, mitochondrial-generated
ROS were also shown to play a role in oxygen sensing (under
hypoxia) leading to HIF activation [20–22].
Overall, these observations suggest that ROS generated by
mutated SDH could play an active role in mutagenesis and
pseudo-hypoxia leading to tumorigenesis. However, experi-
mental studies have failed to confirm the involvement of ROS in
SDH-mutated tumours [14,16]. Recently, an alternative model
based on a metabolic signalling pathway was shown to link
SDH inactivation to pseudo-hypoxia [23]. This pathway, in
which succinate functions as a messenger between mitochon-
drial and cytosolic compartments, has been supported by
metabolomic studies of primary tumours and additional
biochemical studies [16,24,25]. All in all, there is an ongoing
debate regarding the biochemical cause for HIF activation in
SDH-mutated tumours. It is important to elucidate this cause as
it may indicate ways of treating these tumours. If ROS are the
primary cause, then it is likely that antioxidants can be used
either as a preventive treatment (in families carrying SDH
mutations) or as a potential treatment. However, if succinate is
the relevant player in pseudo-hypoxia, increasing intracellular
levels of α-ketoglutarate may overcome this effect [26].
2. Materials and methods
2.1. Materials
Dihydroethidium (DHE) and 2′7′dichlorodihydrofluorescein diacetate
(DCFDA) were purchased from Molecular Probes; antimycin A, ascorbate
and N-acetyl cysteine were purchased from Sigma; ThioGlo-1 was purchased
from Calbiochem.
2.2. Plasmids
The scrambled and the SDHD-targeting siRNA short hairpins, Sc and Di3,
respectively, which were previously described [23], were now cloned into
pSUPER.neo+GFP (OligoEngine).
2.3. Cell culture and transfection
HEK293 cells were incubated routinely at 37 °C, 5% CO2 in DMEM
containing 25 mM glucose and supplemented with 10% foetal calf serum(FCS) and 50 μM β-mercaptoethanol. CCL16-B9 and CCL16-B30 Chinese
Hamster lung fibroblasts were grown in DMEM containing 25 mM glucose
supplemented with 10% FCS, 50 μM β-mercaptoethanol, 1× non-essential
amino acids (Gibco), 2 mM glutamine and 2 mM pyruvate. Cells were
transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen)
according to manufacturer's instructions.
2.4. Glutathione detection
Cells were treated as indicated and lysed using a lysis buffer (Cell Signaling)
freshly supplemented with protein inhibitor cocktail for mammalian tissues
(Sigma). Immediately following centrifugation to clear the lysates, aliquots of
the supernatant were assayed for GSH in 25 mM KH2PO4 (pH 7.2) containing
20 μM ThioGlo-1 (Calbiochem) and for total glutathione after adding 100 μM
NADPH and 3.5 U/ml glutathione reductase. Florescence intensities were
monitored using an excitation wavelength of 405 nm and emission wavelength
of 485 nm and were converted to GSH concentrations by comparison with
standards.
2.5. Analysis of SDH activity
Succinate-DCIP oxidoreductase activity was carried out as was previously
described[23].
2.6. Protein analysis
Cells were extracted in Laemmli sample buffer. Following SDS-PAGE,
proteins were blotted onto nitrocellulose and probed with the following
antibodies: anti-human HIF1α (clone 54; BD Biosciences) or anti-multi-
species HIF1α (clone H1alpha67; Abcam) or anti-actin (clone AC-40;
Sigma).3. Results
Two models have emerged to explain HIFα stabilization
resulting from SDH mutations. The first concerns the effects
of ROS arising from an impaired complex II of the ETC in
which ROS are proposed to inhibit PHDs as a result of
cofactor oxidation. The second points to signalling mediated
by succinate originating from a blocked TCA cycle which
inhibits PHD activity by product inhibition. Although ROS
can arise in some SDH-mutated mitochondria, no evidence
supports their role in mediating HIFα stabilization in SDH-
deficient tumours. To test this possibility, a small interfering
RNA (siRNA), termed Di3 which has previously shown to
effectively knockdown SDH activity in human embryonic
kidney HEK293 cells [23], was cloned into pSuper.neo+GFP
vector. This vector, once transfected into cells, co-expresses
green fluorescent protein (GFP) and the Di3 small hairpin
RNA (shRNA) that targets the SDHD subunit, hence GFP-
positive cells are effectively deficient in SDH activity.
Following transient transfection with this vector, ROS levels
were monitored using the probe dihydroethidium (DHE)
which undergoes oxidation by superoxide to form a red
fluorescent product. Superoxide formed by one electron
reduction of molecular oxygen can serve as progenitor for
other ROS such as hydrogen peroxide, hydroxyl radical and
peroxynitrite and was thus selected for measurement. The
combination of dihydroethidium and GFP allow ROS
generation (red) in cells deficient in SDH activity (green) to
be assessed. The presence of simultaneous green and red
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superoxide by SDH inhibition. As can be seen from Fig. 1A,
whilst some scattered cells are positive for DHE oxidation,
these are not necessarily the SDH-deficient (green) cells.
Moreover, there is no change in the degree or pattern of fluo-
rescence of control cells transfected with a scrambled shRNA-
encoding pSuper.neo+GFP vector (Sc) compared to that of the
SDHD-specific Di3-transfected cells (Fig. 1A). These results
indicate that superoxide formation is not evident in SDH-
deficient cells relative to control cells.
Reduced glutathione (GSH) is the most abundant non-
enzymatic antioxidant in cells and is crucial for scavenging
ROS. GSH removes hydrogen peroxide in a reaction
catalyzed by glutathione peroxidase which generates GSSG;
GSSG is then reduced to GSH by glutathione reductase. In
normal cells, ∼90–95% of the glutathione pool is GSH and
∼5–10% GSSG. A decrease in [GSH], increase in [GSSG]
and decrease in GSH/GSSG ratio are indicative of ROS
production and oxidative stress. The fluorescent thiol reagent
ThioGlo-1 was used to measure GSH levels in cell extracts
before and after the addition of glutathione reductase which
was used to convert GSSG to GSH in the presence of
NADPH. Using this methodology, the GSH/GSSG ratios ofFig. 1. (A) ROS were not detected in SDH-deficient cells. HEK293 cells were transfe
the SDHD-targeting shRNA (Di3). Forty eight hours after transfection cells were
(determined by dihydroethidium oxidation to red-fluorescent ethidium) was analysed
efficiently transfected with the indicated shRNA. (B) SDH inactivation had no appa
treated with 2 μM antimycin A (AA) for 12 h or transfected with the control scramble
48 h. The ratio of reduced (GSH) to oxidized (GSSG) glutathione was used as an indic
more oxidized state, SDH inactivation has no effect on the redox state.untreated, Sc- or Di3-transfected cells were calculated.
Antimycin A was used as a positive control to induce
superoxide production resulting from inhibition of complex III
of the electron transport chain. While the inhibition of
complex III with antimycin A has a marked effect on the
GSH/GSSG ratio compared to untreated and control Sc-
transfected cells, no effect was observed following the
inhibition of complex II (SDH) with the Di3 shRNA (Fig.
1B). This observation corroborates and extends the data from
the DHE experiments (Fig. 1A) and strongly suggests that no
detectable alteration in the redox state of cells is observed
following the inhibition of SDH.
To more convincingly determine whether ROS are
responsible for HIFα induction following SDH inhibition,
cells were pre-treated with the potent antioxidants ascorbate
and N–acetyl cysteine prior to either hydrogen peroxide
treatment or transfection with the shRNAs. To confirm the
effectiveness of the antioxidant regimen, cells were pre-
incubated with or without antioxidants prior to treatment with
hydrogen peroxide. The hydrogen peroxide detector, 2′7′
dichlorodihydrofluorescein diacetate (DCFDA) was added
before extracting the cells and DCFDA oxidation was
fluorescently assessed. As can be seen in Fig. 2A, thected with pSUPER.neo+GFP encoding either control scrambled shRNA (Sc) or
loaded with 10 μM dihydroethidium (DHE) for 30 min. Superoxide levels
microscopically. Green fluorescence (GFP-expressing) denotes cells which were
rent effect on the redox state of cells. HEK293 cells were either left untreated,
d shRNA-expressing plasmid (Sc) or with the SDHD-targeting shRNA (Di3) for
ator of the redox state of the cells. While antimycin A efficiently shifted cells to a
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added to the cells. Moreover, as was previously described
[27,28], hydrogen peroxide led to the accumulation of HIF1α
protein (a HIFα prototype) under normoxic conditions and
treatment with the antioxidants effectively prevented HIF1α
induction in hydrogen peroxide-treated cells (Fig. 2B left
panel). By contrast, antioxidants did not block HIF1α
accumulation in cells treated with an SDHD-targeting shRNA.
(Fig. 2B right panel). These results indicate that while
antioxidant treatment has a strong protective effect against
PHD inhibition mediated by hydrogen peroxide, it has no effect
on PHD inhibition following SDH inactivation.
Although SDH-knockdown does not lead to increased
ROS production in cells, the possibility remained that
aberrant SDH activity in tumours with a mutated form of
SDH may lead to ROS generation. One technical difficulty to
testing this hypothesis is the lack of tumour-derived cell lines.
We therefore used SDHC-mutated hamster fibroblast cells,
CCL16-B9 (B9), which have been previously characterised
[29]. These cells contain a point mutation in the SDHC geneFig. 2. (A) Antioxidants efficiently remove exogenously added hydrogen peroxide. H
acetyl cysteine and 2 mM ascorbate] for 2 h. Cells were incubated for 30 min with 20
hydrogen peroxide. Cells were extracted in RIPA buffer 3 h later and DCFDA ox
prevented HIF1α induction in hydrogen peroxide-treated cells but not in SDH-defi
500 μM hydrogen peroxide or transfected with control scrambled shRNA (Sc) or wi
blot. CoCl2-treated cells (CC) were used as a positive control for HIF1α inductionresulting in premature termination of translation of the
protein. We first compared SDH activity in B9 cells to its
activity in cells reconstituted with an SDHC-GFP fusion
protein (B30) [30] and confirmed lack of SDH activity in B9
cells and a significant recovery of SDH activity in B30 cells
(Fig. 3A). Next, we compared ROS production and
established that, despite a marked reduction in SDH activity
due to the mutation in SDHC, no increase in DHE oxidation
could be detected in B9 cells compared to B30 cells (Fig.
3B). On the other hand, HIF1α protein level under normoxic
conditions was higher in B9 cells compared to B30 cells (Fig.
3C). These results reinforce the previous conclusion that SDH
inactivation does not necessarily lead to ROS production and
that pseudo hypoxia in SDH-deficient cells can be observed
in the absence of redox stress. It is however important to
mention that not much is known about the hamster HIFα
protein(s), and the protein observed in Fig. 3C is of ∼65 kDa,
a considerably lower molecular weight than that of HIF1α of
other species. However, the level of this detected protein was
significantly elevated under hypoxic conditions and whenEK293 cells either left untreated or pre-treated with antioxidants (AO) [2 mMN-
μMDCFDA (Molecular Probes) before further treating with or without 500 μM
idation was analyzed in the lysate using a spectrofluometer. (B) Antioxidants
cient cells. HEK293 cells were treated with antioxidants (AO) with or without
th shRNA targeting SDHD (Di3). HIF1α protein level was detected by western
and actin level was used as a loading control.
Fig. 3. (A) SDH activity was analyzed as was previously described [23] in the SDHC-mutated B9 cells and in the SDHC-reconstituted B30 cells. (B) ROS level was not
increased in B9 cells compared to B30 cells. Cells were incubated with DHE and analyzed microscopically as described in Fig. 1. (C) HIFα protein level is elevated in
the SDH-deficient B9 cells compared to B30 cells. Actin was used as a loading control.
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indeed a HIFα protein (data not shown).
4. Discussion
Although mutations in the B, C or D subunits of SDH
have been predicted (and in one case of SDHC has been
observed) to increase ROS production by restricting electron
flow through complex II, there is currently no evidence which
supports the contention that ROS mediates HIF1α stabiliza-
tion in SDH-deficient cells. Indeed, to the contrary, the data
presented here show that siRNA suppression of SDH activity
stabilized HIF1α by a mechanism independent of ROS
production. By using an RNA interference technique to
transiently target SDH in cells and by using cells which are
carrying an endogenous SDHC mutant, we have demonstrated
both that SDH-inhibited cells do not generate ROS and that
antioxidant treatment does not block HIF1α induction in
transfected cells. These considerations, and the fact thattumours with SDH mutations fail to exhibit signs of oxidative
stress, indicate that an alternate mechanism, namely metabolic
signalling mediated by succinate, is likely to account for HIF
stabilization under the pseudo-hypoxic conditions observed in
SDH deficiency.
The present observations have important clinical implica-
tions as they indicate that antioxidants will not be effective in
blocking HIF activation seen in SDH-deficient tumours. By
contrast, PHD activity and thus normal low HIF1α levels in
these tumours may be restored by any treatment which
decreases or diverts succinate away from PHD and/or increases
the concentration of α-ketoglutarate. Because HIF accumula-
tion may promote tumour progression, drugs that inhibit HIF
and its downstream targets may be useful in treating
carcinomas. We suggest that manipulation of intracellular
concentrations of key metabolic intermediates such as succinate
and α-ketoglutarate with the capability to modulate PHD
activity may provide the basis for a metabolic approach to
cancer chemotherapy.
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